Lyell Immunopharma, Inc.
ronde-cel
large B-cell lymphoma (LBCL)
Countdown
178days
FDA decision · ~ Jan 1, 2027 estimated
What's at stake
The FDA's approval decision on ronde-cel for large B-cell lymphoma (LBCL) is due ~ Jan 1, 2027. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 12h ago
“submission of a Biologics License Application (BLA) to the FDA expected to follow in 2027.”